Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.
National Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Ann Neurol. 2020 Feb;87(2):281-288. doi: 10.1002/ana.25650. Epub 2019 Dec 12.
Febrile seizures may follow vaccination. Common variants in the sodium channel gene, SCN1A, are associated with febrile seizures, and rare pathogenic variants in SCN1A cause the severe developmental and epileptic encephalopathy Dravet syndrome. Following vaccination, febrile seizures may raise the specter of poor outcome and inappropriately implicate vaccination as the cause. We aimed to determine the prevalence of SCN1A variants in children having their first febrile seizure either proximal to vaccination or unrelated to vaccination compared to controls.
We performed SCN1A sequencing, blind to clinical category, in a prospective cohort of children presenting with their first febrile seizure as vaccine proximate (n = 69) or as non-vaccine proximate (n = 75), and children with no history of seizures (n = 90) recruited in Australian pediatric hospitals.
We detected 2 pathogenic variants in vaccine-proximate cases (p.R568X and p.W932R), both of whom developed Dravet syndrome, and 1 in a non-vaccine-proximate case (p.V947L) who had febrile seizures plus from 9 months. All had generalized tonic-clonic seizures lasting >15 minutes. We also found enrichment of a reported risk allele, rs6432860-T, in children with febrile seizures compared to controls (odds ratio = 1.91, 95% confidence interval = 1.31-2.81).
Pathogenic SCN1A variants may be identified in infants with vaccine-proximate febrile seizures. As early diagnosis of Dravet syndrome is essential for optimal management and outcome, SCN1A sequencing in infants with prolonged febrile seizures, proximate to vaccination, should become routine. ANN NEUROL 2020;87:281-288.
发热性惊厥可能与疫苗接种有关。钠通道基因 SCN1A 的常见变异与发热性惊厥有关,SCN1A 中的罕见致病性变异导致严重的发育性和癫痫性脑病——德拉韦特综合征。接种疫苗后,发热性惊厥可能会引起不良预后的担忧,并不合理地将疫苗接种作为病因。我们旨在确定在首次发热性惊厥发生于疫苗接种前后(n=69)或与疫苗接种无关(n=75)的儿童中,SCN1A 变异的发生率与对照组相比是否更高。
我们对在澳大利亚儿科医院招募的首次发热性惊厥且无癫痫发作史的儿童(n=90)、疫苗接种前后(n=69)和非疫苗接种前后(n=75)的前瞻性队列进行 SCN1A 测序,测序过程中不考虑临床类别。
我们在疫苗接种前后的病例中发现了 2 种致病性变异(p.R568X 和 p.W932R),这两种变异均导致了德拉韦特综合征,而非疫苗接种前后的病例中发现了 1 种致病性变异(p.V947L),该病例有热性惊厥伴发,从 9 个月开始。所有病例均有持续>15 分钟的全身性强直阵挛性发作。我们还发现,与对照组相比,发热性惊厥儿童中报告的风险等位基因 rs6432860-T 明显富集(比值比=1.91,95%置信区间=1.31-2.81)。
在疫苗接种后出现发热性惊厥的婴儿中,可能会发现致病性 SCN1A 变异。由于早期诊断德拉韦特综合征对最佳管理和预后至关重要,因此,对于发热性惊厥且接种疫苗后时间较短的婴儿,应常规进行 SCN1A 测序。